Lundbeck posts positive Phase IIa results with Lu AG09222
Danish CNS specialist Lundbeck (LUND: CO) has announced positive results of the HOPE trial, a clinical proof of concept trial of Lu AG09222 as a potential treatment for the prevention of migraine.
The primary analysis concluded that there was a statistically-significant difference (p=0.01) between Lu AG09222 and placebo in the mean change from baseline in the number of monthly migraine days over weeks 1 to 4.
The Phase IIa double-blind, placebo-controlled trial of Lu AG09222 was designed to assess the efficacy, safety, and tolerability of a single intravenous infusion of Lu AG09222. The trial consisted of a four-week, double-blind treatment period, and an 8-week follow-up period after the last dose. A total of 237 patients were randomized in the trial.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze